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Beta blocker specificity:
a building block toward personalized medicine
Brent R. DeGeorge Jr. and Walter J. Koch
Center for Translational Medicine and George Zallie and Family Laboratory for Cardiovascular Gene Therapy,
Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Drugs known as beta blockers, which antagonize the β-adrenergic receptor
(β-AR), are an important component of the treatment regimen for chronic
heart failure (HF). However, a significant body of evidence indicates that
genetic heterogeneity at the level of the β1-AR may be a factor in explaining
the variable responses of HF patients to beta blockade. In this issue of the
JCI, Rochais et al. describe how a single amino acid change in β1-AR alters
its structural conformation and improves its functional response to carvedilol, a beta blocker currently used in the treatment of HF (see the related
article beginning on page 229). This may explain why some HF patients
have better responses not only to carvedilol but to certain other beta blockers as well. The data greatly enhance our mechanistic understanding of
myocardial adrenergic signaling and support the development of “tailored”
or “personalized” medicine, in which specific therapies could be prescribed
based on a patient’s genotype.
Chronic heart failure (HF) poses a major
public health problem in this country,
primarily due to the increasing proportion of our society surviving to the seventh and eighth decades of life and to
improved treatment of acute ischemic
cardiac events, resulting in more surviNonstandard abbreviations used: AC, adenylyl
cyclase; β-AR, β-adrenergic receptor; FRET, fluorescence
resonance energy transfer; GPCR, G protein–coupled
receptor; HF, heart failure.
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vors who develop cardiac dysfunction.
The group of drugs known as beta blockers block the effects of catecholamines,
such as epinephrine and norepinephrine,
on the body’s β-adrenergic receptors
(β-ARs), slowing nerve impulses traveling through the heart and reducing the
heart’s workload. While β-AR antagonists have become a mainstay of HF therapy, the most recent guidelines from the
American College of Cardiology and the
American Heart Association acknowledge
that there are unresolved issues concerning the use of these drugs for the treatment of HF (1).
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β1-AR polymorphisms and
cardiac phenotype
The β-ARs are members of the G protein–
coupled receptor (GPCR) superfamily,
which consists of over 700 genes that are
the targets of more than 50% of the drugs
in clinical practice (2). There are 3 known
types of β-ARs, β1, β2, and β3. The β1-ARs are
located mainly in the heart, kidney, and adipose tissue. The β2-ARs are located mainly
in the heart, lung, gastrointestinal tract,
liver, pancreas, and skeletal muscle. The role
and location of β3-ARs are less well defined.
When stimulated by agonists, β-ARs
primarily activate heterotrimeric guanine
nucleotide–binding (G) proteins of the Gs
family, causing dissociation of Gα-GTP and
Gβγ subunits. The G proteins transduce
intracellular signaling pathways via adenylyl cyclase (AC) activation, and this results
in increased intracellular cAMP levels (3).
This signaling cascade ultimately leads to
positive regulatory input to the myocardial
contractile apparatus. Importantly, β-ARs
present on cardiomyocytes represent the
most powerful means of enhancing the
contractile performance of the heart.
The predominant β-AR subtypes of functional consequence to cardiac physiology
are β1-AR and β2-AR, both of which have
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Figure 1
The effect of the β1-AR Gly389Arg polymorphism on signal transduction and beta blockade by carvedilol. The Gly389Arg polymorphism of the
β1-AR occurs in the region between the seventh transmembrane domain and the intracellular tail of the receptor (R and G correspond to arginine
and glycine, respectively, at position 389 of the receptor). This highly conserved region is putatively associated with coupling to the Gs protein.
The change of the amino acid residue at position 389 of the β1-AR from the polar, basic arginine (upper 3 panels) to the small, nonpolar glycine
(lower 3 panels) may result in a modified structure that could alter receptor-Gs interaction. This region of the cytoplasmic tail of the receptor
may participate in regulating the affinity of the receptor-Gs interaction. This could potentially explain the differences in receptor-Gs coupling and
cAMP production associated with the Arg389 β1-AR variant as compared with the Gly389 β1-AR variant reported previously (7, 8). Under basal
conditions, the Arg389 variant has been associated with increased cAMP production, which is markedly augmented as compared with the Gly389
variant following agonist stimulation (7). This effect could also be attributed to a more favorable structural environment for interaction with Gs.
Carvedilol treatment induces a conformational change resulting in the intracellular tail of the receptor being positioned more closely to the third
intracellular loop; this inverse agonism of the receptor in theory would lead to decreased Gs coupling and reduced cAMP accumulation. Both
variants demonstrated inverse agonist properties in response to carvedilol; however, the effect was increased 2.5-fold in the Arg389 variant,
apparently due to conformation of the Arg389 structure in the presence of the ligand as observed by Rochais et al. in this issue of the JCI (14).

well-documented polymorphisms that
exist in human populations. The coding
region of the gene encoding the β1-AR,
located on chromosome 10q24-26, contains 2 known SNPs resulting in amino
acid substitutions. At position 49 in the
extracellular amino terminus of the receptor, a serine is substituted by a glycine (Ser49Gly) with an allele frequency of 0.87 and
0.13, respectively (4). At position 389 in
the intracellular carboxy terminus in the

proximity of the seventh transmembrane
spanning segment, a glycine or arginine
can be found at an allele frequency of 0.25
and 0.75, respectively (4). These polymorphic variants of the β1-AR appear to have
significant cardiovascular phenotypic
consequences. For example, Ranade et al.
found a significant functional association
between the Ser49Gly polymorphism and
resting heart rate, in which Gly49 homozygotes had the lowest heart rate, and each

The Journal of Clinical Investigation

http://www.jci.org

Volume 117

Ser49 allele increased the basal heart rate in
an additive model (5). The Arg389 variant
appears to be linked with HF in both clinical outcomes and response to therapy (6).
More specifically, the Arg389Gly polymorphism lies within the putative Gs-binding
domain of the β1-AR (Figure 1), and consistent with this localization, previous in vitro
studies in fibroblast cell lines transiently
transfected with the Arg389 β1-AR have demonstrated enhanced receptor-Gs coupling as
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measured by 35S-GTP binding and slightly
increased basal and markedly increased
agonist-induced AC activity as compared
with Gly389 β1-AR–transfected fibroblasts
(7). Furthermore, in a study of transgenic
mice with cardiac-specific overexpression
of Arg389Gly β1-AR variants, Akhter and
colleagues demonstrated that not only does
Arg389 β1-AR lead to increased myocardial
signaling properties, but it also confers cardioprotection following myocardial ischemia
and reperfusion injury (8). This may involve
the upregulation of GPCR kinase 2 (GRK2)
activity, which was presumably induced by
the increased signaling of the Arg389 variant, since the less active Gly389 form did not
alter myocardial GRK2 levels.
In HF, the myocardium has a significant loss of contractile function. In order
to compensate for the loss of systemic
perfusion due to pump failure, the heart
must increase heart rate and contractility.
This is done by increased neurohumoral
activation through increases in the activity of the sympathetic nervous system and
renin-angiotensin system. Increases in
the sympathetic catecholamines norepinephrine and epinephrine lead to chronic
activation of myocardial β-ARs in order to
drive the failing heart. However, chronic
activation of these pathways, in particular
activation of the β1-AR, leads to increased
cardiotoxicity and cardiac pathology
(3). This partially explains the clinical
benefit achieved by β-AR antagonists,
which block the overt noxious effects of
catecholamines and have been shown to
improve survival and reverse pathologic
cardiac remodeling (9). Interestingly, sensitivity to the beneficial effects of β-AR
blockade differs by ethnicity, as evidenced
by data from the Beta-Blocker Evaluation
of Survival Trial (BEST) demonstrating a
lack of benefit in black patients with New
York Heart Association class III or IV HF
treated with the beta blocker bucindolol,
compared with other patients (10). It was
reasoned that racial differences in the incidence of HF and therapeutic response to
β-AR antagonists may be heritable and
that genetic heterogeneity with respect to
β1-ARs may partially account for this phenomenon. However, conflicting data from
clinical studies analyzing the association
of β1-AR polymorphisms and response to
β-AR antagonists have made it difficult to
reach conclusions regarding the true clinical importance of β-AR polymorphisms
with respect to treatment outcome (for
review see ref. 11).
88

β1-AR signaling in real time
Recent advances in the fields of biochemistry
and applied science have generated new classes of fluorescent probes to permit the direct
assessment of the dynamic behavior of biological molecules. Specifically, fluorescence
resonance energy transfer–based (FRET–
based) techniques have allowed investigators
to evaluate dynamic protein-protein interactions and protein conformational changes
in real time (for reviews see refs. 12, 13).
FRET fundamentally characterizes the spatiotemporal relationship of fluorescently
labeled molecules within a system by way of
recording the energy transfer from a donor
fluorophore in an excited electronic state to
an acceptor fluorophore of adequate proximity. In this issue of the JCI, Rochais and colleagues report on their exploitation of FRET
technology to generate a β1-AR FRET sensor
to directly assess the effects of the Arg389Gly
polymorphism in the β1-AR on receptor activation, downstream signal transduction, and
response to beta blockade in cultured human
cells in real time (14). The β1-AR FRET sensor used in this study was generated based
on evidence that the receptor undergoes
conformational changes upon agonist binding, specifically in the region of the carboxy
terminus and third intracellular loop, which
move apart upon receptor activation. The
authors then tagged these regions with
cerulean and yellow fluorescent proteins,
respectively, allowing them to detect the
movement of these regions in real time using
FRET, thereby tracking the dynamic changes
in the receptor in response to agonist and
antagonist binding. The authors demonstrated that this β1-AR FRET sensor shares
pharmacological and signaling characteristics consistent with that of the WT β1-AR,
including similar activation kinetics and
downstream signaling via cAMP formation.
Utilizing β1-AR FRET sensors for both
Gly389 and Arg389 variants of the β1-AR,
the authors were able to directly assess the
functional consequences of β-AR polymorphisms with respect to receptor conformation in response to pharmacologic
agonists and antagonists. In contrast with
results in previous in vitro studies (7, 8),
the authors identified no significant differences between Gly389 and Arg389 variants
in β1-AR–mediated Gs coupling or cAMP
accumulation in response to agonist (14).
Perhaps the most exciting clinically relevant data from this study is the comparison of the FRET responses of the 2 β1-AR
variants generated by the β-AR antagonists
bisoprolol, metoprolol, and carvedilol.
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Each β-AR antagonist induced an increase
in FRET ratio, signifying the occurrence of
an active change in receptor conformation
upon antagonist binding, suggesting an
inverse agonist mechanism of action on the
β-AR. Increases in FRET ratio were minor
with respect to decreases in receptor activation for metoprolol and bisoprolol, and the
effects of these 2 beta blockers did not differ between β1-AR variants (14). In contrast,
carvedilol induced strong inverse agonism
with regard to both β1-AR variants; furthermore, the Arg389 β1-AR variant exhibited a
2.5-fold increase in FRET ratio as compared
with the Gly389 β1-AR variant. The unique
properties of this beta blocker were confirmed downstream of receptor inactivation
at the level of decreased cAMP accumulation: both β1-AR variants demonstrated
marked reduction in basal cAMP levels (14).
Carvedilol led to a much stronger reduction
in basal cAMP content in the Arg389 β1-AR
variant as compared with the Gly389 β1-AR
variant (see Figure 1). The authors further
established the phenotypic relevance of
the molecular alterations induced by the
Arg389Gly polymorphisms using primary
neonatal rat cardiac myocytes infected with
adenoviruses containing the β1-AR variants
as a model system to study cardiac rate control. Under basal conditions, both β1-AR
variants induced an increase in contractile
activity as compared with WT cardiac myocytes; however, the contractile activity of the
Arg389 variant was increased nearly 1.5-fold
as compared with the Gly389 variant, and
carvedilol significantly decreased this activity preferentially in the Arg389 β1-AR.
Overall, the study by Rochais et al. (14) represents the first direct assessment of GPCR
function using the well-characterized β1-AR
system that also happens to be critical for
normal and pathological cardiac physiology. Of importance, the authors were able
to assess the conformational changes that
occurred during agonism and antagonism
of the receptor. Moreover, the data reveal
that different β1-AR antagonists, particularly carvedilol, are capable of inducing varying
degrees of inverse agonism on the receptor
and that this effect of carvedilol is dependent on the amino acid residue present at
position 389 of the β1-AR. Carvedilol, unlike
metoprolol or bisoprolol, is a nonselective
beta blocker and can also act on α1-ARs (15).
Therefore, it would be interesting to address
the potential effects of β2-AR and α1-AR signaling on cardiac rate control to ascertain
whether any receptor crosstalk or dimerization is responsible for the decreased basal
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cAMP production mediated by the Arg389
variant or whether antagonism of these other
receptors is involved in the beneficial effects
of carvedilol in HF. However, what is important to remember based on the current work
is that for the β1-AR, carvedilol displays the
greatest degree of inverse agonism, especially
for the Arg389 variant (Figure 1), and studies
such as this could lead to research broadening our knowledge of this pharmacological
property of GPCR ligands and therefore
potentially increase their clinical utility (16).
Taking it personally
The implications of these findings are of
potentially profound clinical importance
when considering the interindividual and
ethnic variation that occurs in response to
β-AR blocker therapy in the treatment of HF.
It has been reported that the allele frequency
of the Arg389 variant is 20% less common
in black patients compared with non-black
patients, and this may partially explain the
poorer response to β1-AR antagonists seen
in blacks compared with that of the rest of
the population (17). Future efforts to characterize the effect of genetic heterogeneity in
cellular response to pharmacological agents,
such as the β1-AR antagonists examined in
this study, lend credence to the viability of
the concept of pharmacogenomics — pharmacologic intervention adapted according
to an individual’s genetic makeup — and the

realization of “personalized” medicine for
the treatment of cardiovascular disorders
such as HF (18).
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Macrophage heterogeneity and tissue lipids
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Macrophages are present as resident cells in adipose tissue, and blood
monocytes are recruited in increased numbers to sites of lipid accumulation in atherosclerosis, a modified form of inflammation in the arterial wall.
Recent findings reported by 3 separate groups in this issue of the JCI provide evidence for distinct monocyte subsets, differential chemokine receptor usage, and phenotypic modulation of macrophages in murine models of
genetic and high-fat diet–induced disease (see the related articles beginning
on pages 175, 185, and 195). These studies raise prospects for selective therapeutic targets to ameliorate macrophage hyperinflammatory responses,
while sparing host defense and repair mechanisms.
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chemokine receptor 2; CX3CR1, C-X3-C motif chemokine receptor 1.
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Monocytes and mature macrophages are
prominent in the host response to lipid
accumulation in major arteries, the development of atherosclerotic plaques, and
their complications (1). Less established
are the details of their colocalization and
possible metabolic interactions with adi-
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pocytes in body fat stores (2). New studies
reported in this issue of the JCI by Swirski
et al. (3) demonstrate that a monocyte subset that expresses high levels of a marker
antigen, Ly-6C, dominates hypercholesterolemia-associated monocytosis and gives
rise to macrophages in atheromata. Also
in this issue, Tacke et al. (4) report that
monocyte subsets differentially employ the
chemokine receptors C-C motif chemokine receptor 2 (CCR2), CCR5, and C-X3-C
motif chemokine receptor 1 (CX3CR1,
also known as the fractalkine receptor) to
enter atherosclerotic plaques. They also
exploited an mAb, Gr-1, directed against
Ly-6 family antigens to distinguish monocyte subsets and used CD11c, a β2 integrin
expressed by myeloid DCs and selected tis-
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